{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:19Z","timestamp":1792704019402,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.resinv.2023.05.005","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T21:09:14Z","timestamp":1687640954000},"page":"553-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pulmonary fibrosis and type-17 immunity"],"prefix":"10.1016","volume":"61","author":[{"given":"Satoru","family":"Senoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Higo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2023.05.005_bib1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis an Official ATS\/ERS\/JRS\/ALAT Clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.resinv.2019.12.007","article-title":"Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone","volume":"58","author":"Higo","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.05.005_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236935","article-title":"Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity \u2264 50%: a multi-center retrospective analysis","volume":"15","author":"Senoo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2023.05.005_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2023.05.005_bib6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.resinv.2019.04.003","article-title":"Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Higo","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.05.005_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","article-title":"Japanese guideline for the treatment of idiopathic pulmonary fibrosis","volume":"56","author":"Homma","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2023.05.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/16000617.0053-2019","article-title":"The genetics of interstitial lung diseases","volume":"28","author":"Borie","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2023.05.005_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fimmu.2019.00092","article-title":"Type 3 ILCs in lung disease","volume":"10","author":"Ardain","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib12","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.0900036","article-title":"IL-23 drives pathogenic IL-17-producing CD8 + T cells","volume":"182","author":"Ciric","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib13","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1084\/jem.20100061","article-title":"\u03b3\u03b4 T cells protect against lung fibrosis via IL-22","volume":"207","author":"Simonian","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib14","article-title":"Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases","volume":"20","author":"Bunte","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2023.05.005_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1465-9921-14-5","article-title":"IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice","volume":"14","author":"Kurimoto","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2023.05.005_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1165\/rcmb.2016-0015OC","article-title":"IL-23 Is essential for the development of Elastase-induced pulmonary inflammation and emphysema","volume":"55","author":"Fujii","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2023.05.005_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/intimm\/dxv070","article-title":"Innate-like function of memory Th17 cells for enhancing endotoxin-induced acute lung inflammation through IL-22","volume":"28","author":"Sakaguchi","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00117-2019","article-title":"RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation","volume":"5","author":"Sivakumar","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2023.05.005_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3005964","article-title":"Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis","volume":"5","author":"Herazo-Maya","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar8356","article-title":"PD-1 up-regulation on CD4 + T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production","volume":"10","author":"Celada","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1\u03b2\u2013mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib23","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1002\/ctm2.509","article-title":"Protective function of interleukin-22 in pulmonary fibrosis","volume":"11","author":"Gu","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2021.784215","article-title":"Transcriptome sequencing identifies PLAUR as an important player in patients with dermatomyositis-associated interstitial lung disease","volume":"12","author":"Chen","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.resinv.2023.05.005_bib25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/jcm9051356","article-title":"Anti-aminoacyl transfer-RNA-synthetases (anti-tRNA) autoantibodies associated with interstitial lung disease: pulmonary disease progression has a persistent elevation of the Th17 cytokine profile","volume":"9","author":"Ramos-Martinez","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib26","article-title":"Clinical and radiological features of interstitial lung diseases associated with polymyositis and dermatomyositis","volume":"58","author":"Palmucci","year":"2022","journal-title":"Medicina (Lithuania)"},{"key":"10.1016\/j.resinv.2023.05.005_bib27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic TH 17 cells in the absence of TGF-\u03b2 2 signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2023.05.005_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/ni.1717","article-title":"CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets","volume":"10","author":"Ribot","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202049119","article-title":"Evolved to protect, designed to destroy: IL-17-producing \u03b3\u03b4 T cells in infection, inflammation, and cancer","author":"Agerholm","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells-a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.immuni.2015.06.019","article-title":"Interleukin-12 and -23 control plasticity of CD127(+) group 1 and group 3 innate lymphoid cells in the intestinal lamina propria","volume":"43","author":"Bernink","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.resinv.2023.05.005_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2023.05.005_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145961","article-title":"Characterization and quantification of innate lymphoid cell subsets in human lung","volume":"11","author":"de Grove","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib34","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00582.2020","article-title":"Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis","author":"Senoo","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.resinv.2023.05.005_bib35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/eji.202048627","article-title":"Tc17 biology and function: novel concepts","volume":"50","author":"L\u00fcckel","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001255","article-title":"Development and function of invariant natural killer T cells producing T H2- and T H17-cytokines","volume":"10","author":"Watarai","year":"2012","journal-title":"PLoS Biol"},{"key":"10.1016\/j.resinv.2023.05.005_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023185","article-title":"IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis","volume":"6","author":"Gasse","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib38","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.4049\/jimmunol.1004081","article-title":"Blocking IL-17a promotes the resolution of pulmonary inflammation and fibrosis via TGF- 1-dependent and -independent mechanisms","volume":"187","author":"Mi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib39","article-title":"Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-\u03b21 mediated Smad2\/3 and ERK1\/2 activation","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib40","doi-asserted-by":"crossref","first-page":"L487","DOI":"10.1152\/ajplung.00301.2018","article-title":"Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A\/IL-17RA in human fibrotic interstitial lung disease","volume":"316","author":"Zhang","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.resinv.2023.05.005_bib41","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10753-013-9609-z","article-title":"IL-17A\/F modulates fibrocyte functions in cooperation with CD40-mediated signaling","volume":"36","author":"Hayashi","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.resinv.2023.05.005_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1371\/journal.pone.0041394","article-title":"Autophagy in idiopathic pulmonary fibrosis","volume":"7","author":"Patel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1084\/jem.20092054","article-title":"Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A","volume":"207","author":"Sonnenberg","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib44","unstructured":"Lei L, Zhao C, Qin F, He Z-Y, Wang X, Zhong X-N. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol n.d.;34 Suppl 1:14\u201322."},{"key":"10.1016\/j.resinv.2023.05.005_bib45","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1097\/TP.0000000000002837","article-title":"IL-17A contributes to lung fibrosis in a model of chronic pulmonary graft-versus-host disease","volume":"103","author":"Martinu","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.resinv.2023.05.005_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10753-008-9062-6","article-title":"IL-17 producing \u03b3\u03b4 T cells are required for a controlled inflammatory response after bleomycin-induced lung injury","volume":"31","author":"Braun","year":"2008","journal-title":"Inflammation"},{"key":"10.1016\/j.resinv.2023.05.005_bib47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.12802","article-title":"The regulatory role of interferon-\u03b3 producing gamma delta T cells via the suppression of T helper 17 cell activity in bleomycin-induced pulmonary fibrosis","volume":"185","author":"Segawa","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib48","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1111\/jcmm.15475","article-title":"IL-17A-producing T cells exacerbate fine particulate matter-induced lung inflammation and fibrosis by inhibiting PI3K\/Akt\/mTOR-mediated autophagy","volume":"24","author":"Cong","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib49","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.4049\/jimmunol.172.9.5782","article-title":"Treatment with \u03b1-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis","volume":"172","author":"Kimura","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ni.3078","article-title":"IL-25-responsive, lineage-negative KLRG1 hi cells are multipotential \u201cinflammatory\u201d type 2 innate lymphoid cells","volume":"16","author":"Huang","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaci.2018.03.007","article-title":"IL-17-producing ST2+ group 2 innate lymphoid cells play a pathogenic role in lung inflammation","volume":"143","author":"Cai","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1073\/pnas.1315854111","article-title":"IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis","volume":"111","author":"Hams","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.resinv.2023.05.005_bib53","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","article-title":"IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice","volume":"134","author":"Li","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/path.5092","article-title":"An ST2-dependent role of bone marrow-derived group 2 innate lymphoid cells in pulmonary fibrosis","volume":"245","author":"Zhao","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.resinv.2023.05.005_bib55","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jcmm.12341","article-title":"Th17 can regulate silica-induced lung inflammation through an IL-1\u03b2-dependent mechanism","volume":"18","author":"Song","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib56","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.4049\/jimmunol.0900459","article-title":"IL-17A\u2013Producing \u03b3\u03b4 T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis","volume":"184","author":"lo Re","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/209179","article-title":"Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis","volume":"2013","author":"Liang","year":"2013","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.resinv.2023.05.005_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis an international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib60","article-title":"Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis","volume":"16","author":"Enomoto","year":"2018","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.resinv.2023.05.005_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620935774","article-title":"Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis","volume":"14","author":"Enomoto","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2023.05.005_bib62","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/resp.12862","article-title":"Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia","volume":"21","author":"Arai","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2023.05.005_bib63","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2023.05.005_bib64","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial","volume":"201","author":"Kondoh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/01902148.2016.1144835","article-title":"Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis","volume":"42","author":"Wei","year":"2016","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.resinv.2023.05.005_bib67","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/jcmm.13992","article-title":"IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis","volume":"23","author":"Chen","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/mi.2016.86","article-title":"ROR\u03b3t, a multitask nuclear receptor at mucosal surfaces","volume":"10","author":"Eberl","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.resinv.2023.05.005_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib70","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2023.05.005_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0248957","article-title":"The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT","volume":"16","author":"Zou","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2023.05.005_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103590","article-title":"Post COVID-19 pulmonary fibrosis; a meta-analysis study","volume":"77","author":"Hama Amin","year":"2022","journal-title":"Annals of Medicine and Surgery"},{"key":"10.1016\/j.resinv.2023.05.005_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107828","article-title":"Different T cell related immunological profiles in COVID-19 patients compared to healthy controls","volume":"97","author":"Mahmoud Salehi Khesht","year":"2021","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.resinv.2023.05.005_bib74","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/jcp.30047","article-title":"Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls","volume":"236","author":"Sadeghi","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.resinv.2023.05.005_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155627","article-title":"Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: a pilot study","volume":"146","author":"Avdeev","year":"2021","journal-title":"Cytokine"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534523000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:32:37Z","timestamp":1761949957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534523000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2212534523000564"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2023.05.005","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary fibrosis and type-17 immunity","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2023.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}